Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) was the target of a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 3,889 shares, a growth of 193.1% from the May 14th total of 1,327 shares. Currently, 2.3% of the shares of the company are sold short. Based on an average daily volume of 1,517 shares, the days-to-cover ratio is currently 2.6 days.
Amplify Weight Loss Drug & Treatment ETF Stock Performance
Shares of Amplify Weight Loss Drug & Treatment ETF stock traded down $0.11 on Friday, reaching $24.42. 222 shares of the company were exchanged, compared to its average volume of 2,050. The company’s 50-day moving average is $24.55 and its two-hundred day moving average is $25.17. The firm has a market cap of $4.15 million, a price-to-earnings ratio of 24.31 and a beta of 0.40. Amplify Weight Loss Drug & Treatment ETF has a 1-year low of $21.70 and a 1-year high of $27.28.
Institutional Trading of Amplify Weight Loss Drug & Treatment ETF
An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC lifted its stake in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Free Report) by 5.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 24,891 shares of the company’s stock after purchasing an additional 1,215 shares during the quarter. Jane Street Group LLC owned about 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 as of its most recent filing with the Securities and Exchange Commission.
Amplify Weight Loss Drug & Treatment ETF Company Profile
The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Read More
- Five stocks we like better than Amplify Weight Loss Drug & Treatment ETF
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Receive News & Ratings for Amplify Weight Loss Drug & Treatment ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Weight Loss Drug & Treatment ETF and related companies with MarketBeat.com's FREE daily email newsletter.
